This is a preview of subscription content, log in via an institution to check access.
REFERENCES
E. De Clercq. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38:2491–2517 (1995).
J. Balzarini, M. J. Pérez-Pérez, S. Velazquez, A. San-Félix, M. J. Camarasa, and E. De Clercq. Suppression of the break-through of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilides derivatives when used individually or in combination with other HIV-1-specific inhibitors. Proc. Nat. Acad. Sci., USA 92:5470–5474 (1995).
J. Balzarini, W. G. Brouwer, D. C. Dao, E. M. Osika, and E. De Clercq. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild type virus. Antimicrob. Agents Chemother. 40:1454–1466 (1996).
J. Balzarini, H. Pelemans, S. Aquaro, C. F. Perno, M. Witvrouw, E. De Clercq, and A. Karlsson. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 50:394–401 (1996).
R. W. J. Buckheit, T. L. Kinjerski, V. Fliakas-Boltz, J. D. Russell, T. L. Stup, L. A. Pallansch, W. G. Brouwer, D. C. Dao, W. A. Harrison, and R. J. Schultz. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:2718–2727 (1995).
J. B. McMahon, R. W. J. Buckheit, R. J. Gulakowski, M. J. Currens, D. T. Vistica, R. H. Schoemaker, S. F. Stinson, J. D. Russell, J. P. Bader, V. L. Narayanan, R. J. Schultz, W. G. Brouwer, E. E. Felauer, and M. R. Boyd. Biological and biochemical antihuman immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J. Pharmacol. Exp. Ther. 276:298–305 (1996).
P. V. Balimane, V. Makhey, and P. J. Sinko. Study of the transport characteristics of a novel thiocarboxanilide pentenyloxy ether derivative UC-781: an inhibitor of human immunodeficiency virus type-1 replication. Pharm. Res. 14:S-31 (1997).
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265–275 (1951).
K. F. Ilet, L. B. G. Tee, P. T. Reeves, and R. F. Minchin. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmac. Ther. 46:67–93 (1990).
V. J. Wacher, L. Salphati, and L. Benet. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Del. Rev. 20:99–112 (1996).
P. H. de Waziers, P. H. Cugnenc, C. S. Yang, J. P. Leroux, and P. H. Beaune. Cytochrome P450 isoenzymes, epoxide hydrolase, and gluthathione transferase in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387–394 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van den Mooter, G., Stas, G., Damian, F. et al. Stability of UC-781, in Intestinal Mucosal Homogenates of the Rat, Rabbit, and Pig. Pharm Res 15, 1799–1802 (1998). https://doi.org/10.1023/A:1011985418360
Issue Date:
DOI: https://doi.org/10.1023/A:1011985418360